The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Pitmans LLP

Work +44 345 222 9222
Fax +44 118 958 5097

Show all Press releases

Pitmans acts for Novacyt S.A on its acquisition of Primer Design Limited

July 2016

Pitmans LLP, led by partner Philip Weaver, assisted by director Jasmine Murphy and solicitor Laurel Knight, has acted for Novacyt S.A, a leader in the field of cellular diagnostics, specialising in cancer and infectious disease diagnostics, on its acquisition of Primer Design Limited (Primer Design).

Primer Design is a leading molecular biology specialist. Its specialist real-time Polymerase Chain Reaction (PCR) technology (a technique for amplifying and copying DNA in real-time to allow for greater data production and analysis) has developed molecular biology across the world. The acquisition will enable Novacyt S.A, a company listed on the Alternext market in France, and its group companies (including Lab 21 based in Cambridge), to extend their global reach by adding to their technology, allowing them to provide wider ranging advanced molecular diagnostics.

Novacyt CEO Graham Mullis commenting on the transaction said: This is another significant milestone in our ambitious growth plan. Our investors recognise the strategic rationale of combining Primer Design’s non-clinical molecular diagnostic products with Novacyt’s regulatory and sales infrastructure. I am excited at the potential of the unified group to accelerate growth and deliver the identified significant strategic and operational synergies.”

Philip Weaver stated: “We were delighted to act for Novacyt in one of its most significant acquisitions in recent years and we look forward to continuing our involvement with the Novacyt Group which has changed almost beyond recognition since we first started to act for Lab21 Limited seven years ago.”

Legal Developments in the UK

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to